Physiomics plc (AIM: PYC) has secured new contracts worth more than £205,000, extending a strong run of commercial wins for the mathematical modelling, data science and biostatistics specialist.
MedPal AI Strengthens Board as £28m Revenue Run Rate Drives Growth Incentive Package
MedPal AI plc (AIM: MPAL; FRA: Z1N) has appointed former eEnergy Group chief executive Harvey Sinclair as an independent non-executive director as the digital health group looks to strengthen its
Genflow Biosciences Trial Meets Primary Endpoint in Aged Beagles
Genflow Biosciences Ltd (LON: GENF) has reported that its SLAB clinical trial evaluating the company’s SIRT6 centenarian gene therapy in aged beagles has met its primary endpoint.
Novacyt Launch of IVDR-Certified Yourgene® Insight DPYD Assay
Novacyt (AIM: NCYT) has launched its IVDR-certified Yourgene® Insight DPYD assay across regulated European markets, expanding the company’s clinical genetics portfolio.
MedPal AI plc – From zero to £28 million annualised in ten months
MedPal AI plc (AIM: MPAL) has reported a sharp acceleration in trading, with its New Health GLP-1 weight-management business generating £1.83 million of revenue in August, an increase of more
Avacta pays £2.61m bond instalment as debt falls to £12m
Avacta Therapeutics (AIM: AVCT) has settled an accelerated deferred convertible bond repayment of £2.613 million in cash, reducing the remaining principal under the facility to £12 million.
Mounjaro wins US approval to cut heart attack and stroke risk
MedPal AI plc (AIM: MPAL) has highlighted the potential expansion of the GLP-1 market after the US Food and Drug Administration approved Eli Lilly’s Mounjaro to reduce the risk of
Avacta Awards CEO 13.4m Share Options at 69p as Clinical Pipeline Advances
Avacta (AIM: AVCT) has granted a substantial package of share options to its management team, including 13.4 million options to chief executive Christina Coughlin, as part of an incentive and
GENinCode Shares Jump 23% as CARDIO inCode Study Shows Improved Coronary Risk Prediction
GENinCode Plc (AIM: GENI) shares rose around 23% in early trading after the predictive genetics company reported encouraging clinical results for its CARDIO inCode-Score® test in the prevention of coronary
Nuformix Appoints Tim Metcalfe as Non-Executive Chairman
Nuformix plc (LON: NFX) has appointed Tim Metcalfe as Non-Executive Chairman, with the role taking effect from 1 September 2026.
Nuformix Reports Positive NXP002 Inhalation Study Results
Nuformix plc (LON: NFX) has reported positive preclinical results for NXP002, its potential inhaled treatment for idiopathic pulmonary fibrosis and other progressive fibrosing lung diseases.
MedPal highlights new UK oral weight-loss treatment
MedPal AI plc (AIM: MPAL) has highlighted the UK approval of Eli Lilly’s once-daily oral GLP-1 treatment, Foundayo, which has been authorised for weight loss and weight maintenance in eligible